Positioned to transform the HBV treatment landscape and address the HBV global market opportunity



Learn How >



Portfolio of assets combining multiple technologies aimed at curing HBV



Learn How >



Robust pipeline combines near-term catalysts with long-term value creation potential



Learn How >



Proven scientific leadership in antiviral and RNAi drug discovery and development



Learn How >

About Arbutus Biopharma

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

 

In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

 

Read More